Sotrovimab
- Generic Name
- Sotrovimab
- Brand Names
- Xevudy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2423014-07-5
- Unique Ingredient Identifier
- 1MTK0BPN8V
- Background
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.
Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.
- Indication
In Europe, sotrovimab is indicated for the treatment of COVID-19 in patients ≥12 years old and weighing ≥40kg who do not require supplemental oxygen and are at high risk of progressing to severe disease.
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19)
- Associated Therapies
- -
FDA bans use of Lilly, Regeneron COVID drugs due to Omicron
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.